Just had a thought.... although we lament that once upon a time...

Just had a thought.... although we lament that once upon a time we only had 200 Million shares on issue and now it will be more like 390 Million.

Much has changed.
Back then we had APAS, No sales and a marketing agreement and a market of 2000 Labs, impressive dollars if you converted 20%.

Fast forward to now our market will increase to 27,000 microbiology labs with the introduction of the APAS Compact.
What I find interesting is depending on the manufacturing cost of the Compact its could be offered as a operating expense
Pay $10,000 US a year plus the cost of the Analysis Modules $30,000 US
Its the Analysis modules Licensing fees re-occurring yearly that will really drive revenue at $46,000 Australian.

By my calculations there is approximately 25,000 Non-Clinical labs Manufacturing wise around the world an ideal market for the APAS Pharma.
So potentially our market grew from 2000 labs to potentially 52,000 labs.

2% of the 52,000 labs being 1000 machine sales produce yearly revenue of $46 Million.

So our market grew 26 times with the introduction of APAS Pharma and APAS Compact.

With a US distributor and soon a European distributor and potentially a Collaboration with a large Pharmaceutical company I would have to say LBT is getting interesting again.